 The trial will also determine whether the World Health Organizations WHO recently recommended 2 dose strategy for girls aged under 15 years produces similar immune responses in Sub-Saharan Africa SSA compared to the previously recommended 3 dose schedule. In addition, the cost-effectiveness of alternative dosing schedules and of the two vaccines will be explored. 